Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prana discovers new drug candidates for Parkinson’s research
Prana’s drug candidates are being tested on two widely used mouse models for Parkinson’s disease, which employ either the 6-hydroxy-dopamine (6-OHDA) or MPTP toxins. These models mimic the
Prana’s drug candidates are being tested on two widely used mouse models for Parkinson’s disease, which employ either the 6-hydroxy-dopamine (6-OHDA) or MPTP toxins. These models mimic the
According to the company, Artemis’s 3D/4D imaging allows doctors to select and biopsy a location within the boundary of the prostate with pinpoint accuracy. The biopsy location is
Stiefel will acquire all shares of ABR Invent and ABR Development through a definitive stock purchase agreement. Both ABR Invent and ABR Development are legal entities based in
Under terms of the agreement, Konica Minolta Opto (KMOT) will have a defined period of time to evaluate certain applications of Guided Therapeutics’s (GT’s) technology, including the potential
The financing will fund the company through 2010. It will be used to advance Apoptos’s portfolio of small molecule drugs that are directed at inducing tumor cell apoptosis,
The company does not anticipate any disruption in its service to customers as these changes occur. Affected employees, who are located throughout the US, will be notified by
The European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have formed a strategic partnership to promote innovative research projects and help accelerate the discovery
According to the Association of the British Pharmaceutical Industry (ABPI), the government’s move is likely to have potential repercussions in the pharma sector with many pharma companies considering
The survey found that 35% of the companies polled expected to cut their investment in R&D over the next 12 months, while 46% plan to conduct fewer clinical
In this new collaboration, BioFocus DPI will provide assay development and high-throughput screening services for several Allergan targets. Furthermore, BioFocus DPI’s computational chemists plan to work together with